{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"320"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"The MTD plerixafor in combination with bortezomib is determined by the number of patients who experience a dose limiting toxicity (DLT). See subsequent primary outcome measure for the DLT definition. The MTD is defined as highest dose level at which fewer than one-third of patients experience a DLT. The MTD was reached at dose level 5B. The maximum tolerated dose of plerixafor was given on days 1, 2, 3, 6, 10, 13 of 21 each cycle.","groups":[{"description":"All Phase I participants received plerixafor by injection and bortezomib intravenously according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.","id":"OG000","title":"All Phase I Particiapnts"}],"paramType":"NUMBER","populationDescription":"All Phase I participants who received at least one dose of the study drug were evaluable for MTD.","reportingStatus":"POSTED","timeFrame":"Participants were assessed every 3 weeks while on study; The observation period for MTD evaluation was the first 21 days of treatment.","title":"Plerixafor Maximum Tolerated Dose (MTD) [Phase I]","type":"PRIMARY","unitOfMeasure":"ug/kg"}